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Objective: Heart valve abnormalities are commonly found in patients with antiphos-
pholipid syndrome but experience with valve replacement in such patients is
limited. We analyzed the results of valve replacement in patients with this condition
at our institution.
Methods: Between 1989 and 2002, 10 patients with antiphospholipid syndrome (8
women, 2 men; aged 38-73 years, mean 49 years) with severe mitral valve disease
(n  7), aortic valve disease (n  2), or combined mitral-aortic disease (n  1)
underwent valve replacement. We reviewed retrospectively their clinical data,
operative and postoperative courses, and the long-term results. Pathological reas-
sessment was performed in all cases.
Results: Procedures performed included mitral valve replacement in 7 patients,
aortic valve replacement in 2 patients, and combined aortic valve replacement plus
mitral valve replacement in 1 patient. In addition, 2 patients underwent tricuspid
annuloplasty. The immediate mortality was 20% (2 patients). Major complications
occurred in 2 other cases. During a follow-up period of up to 8 years, 2 patients
required repeat operation for valve-related complications (1 death). An additional
patient died of cardiac causes 13 months after surgery. One patient had major
thromboembolic events 3 and 10 months after the operation. The late outcome was
uneventful in only 4 patients.
Conclusion: Valve replacement in patients with antiphospholipid syndrome may
carry significant early and late mortality and morbidity, particularly when such
patients are referred with advanced valvular heart disease.
Antiphospholipid syndrome (APLS) is a multisystem autoimmunedisease characterized by arterial and venous thrombosis, recurrentfetal loss, thrombocytopenia, and circulating antiphospholipidantibodies. Virtually any organ can be involved: heart (valvularand coronary disease, intracardiac thrombi), central nervous sys-tem (CNS)/brain (cerebrovascular accident, transient ischemic
attack, seizures, chorea, migraine, pseudotumor cerebri, visual disturbances, demen-
tia), skin (livedo reticularis, ulcers, infarcts, superficial thrombophlebitis), kidney
(renal artery or vein thrombosis, acute and chronic renal failure), and bone (hemo-
lytic anemia).1,2 This syndrome with protean clinical manifestations can be either
primary or secondary to other autoimmune disease, mainly systemic lupus erythem-
atosus (SLE).1,2 Although heart valve abnormalities are found in a majority of
patients with APLS,3 the prognosis of the valvular disease in this condition is not
well documented except for the high incidence of thromboembolic events.4 Signif-
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icant damage necessitating valve replacement is considered
rare,5 and data regarding the outcome of valve replacement
in patients with APLS are limited and generally restricted to
case reports.6-19 To examine our own experience with these
procedures, we reviewed all patients with APLS (primary
and secondary) who underwent valve replacement at our
institution during the last 13 years.
Patients and Methods
Of 2418 patients who underwent valve replacement during the last
13 years at our hospital, 24 patients with either APLS or the
presence of anticardiolipin (ACL) antibodies were identified. Of
these 24 patients, 14 had a transient elevation of ACL antibodies
with no evidence of APLS. Only the remaining 10 patients fulfilled
preliminary classification criteria for definite APLS.20 These 10
patients form the basis of this report.
The preoperative cardiac findings are summarized in Table 1.
There were 8 women and 2 men, who ranged in age from 38 to 73
(mean 49) years. Seven patients had severe mitral valve disease; 1
had combined mitral-aortic valve disease; in 2 male patients the
aortic valve was damaged. Preoperatively, 5 patients were classi-
fied as New York Heart Association (NYHA) functional class IV,
4 were considered class III, and the remaining patient was in class
II. Severe pulmonary hypertension was found in 6 patients. The
main clinical and laboratory characteristics of the underlying
APLS are shown in Table 2. The syndrome was primary in 5 cases
and secondary to SLE in the remaining 5. The mean interval
between the first manifestation of APLS and the first (index)
operation was 9.7 years (1-22 years). Eight patients had arterial or
venous vascular thrombosis in the past. All but 1 patient had CNS
involvement and in all but 1 case thrombocytopenia was found.
Five patients had mild to moderate renal failure (serum creatinine
130-220 mEq/dL). Seven patients were taking prednisone at the
time of operation.
Operative Data
Operative data and outcomes are depicted in Table 3. All opera-
tions were performed using standard cardiopulmonary bypass,
with full heparinization (activated clotting time  480 seconds)
and cardioplegic arrest. Operative procedures included mitral
valve replacement (MVR) in 7 patients, aortic valve replacement
(AVR) in 2 patients, and combined MVR and AVR in 1 patient.
Tricuspid annuloplasty was performed in 2 patients concomitantly
with MVR. Eight patients received mechanical valves, and 2
patients (patients 3 and 8) received tissue valves. Median sternot-
omy was performed in 9 cases, whereas right thoracotomy was
employed in 1 patient.
Oral anticoagulation with warfarin sodium (Coumadin) was
instituted 24 hours postoperatively, and heparin was continued
until the international normalized ratio (INR) achieved a target
value of 3 to 4. None of the patients (8 of them with preoperative
thrombocytopenia) received antiplatelet therapy during the early
postoperative period.
Definitions
Early outcomes included events and complications occurring
within the first 30 days after operation or during hospital stay.
Complications were defined according to guidelines for reporting
morbidity and mortality after cardiac valvular operations21.
Follow-up
Patients were followed in our outpatient clinic. Recent clinical
evaluation was performed on all surviving patients. The follow-up
period was 6 to 96 months (mean 35 months) with a total of 281
patient-months.
Results
Pathology
For those entering the study, the pathological evaluation
was reassessed. A total of 12 valves from 10 patients were
examined. These included 8 native mitral valves and 2
native aortic valves, 1 prosthetic mitral valve, and 1 aortic
homograft valve. All tissue valves were irregularly thick-
ened, with varying degrees of distortion of the collagen
layers. Chronic inflammatory infiltrates were observed in all
tissue valves to a variable extent. Neovascularization was
observed in 9 cases. Calcification (observed in 5 cases)
varied from none to extensive. Among the native valves, 6
displayed small (0.5 cm in diameter), granular fibrinous
vegetations. These ranged from being flat and visible only
microscopically to raised and rounded or verrucous depos-
its. In 1 case the vegetations completely encircled mitral
annulus at the line of closure. The prosthetic mitral valve
and aortic homografts had similar small vegetations. Micro-
scopically, the observed vegetations in all cases consisted of
fibrin thrombi with minimal inflammatory infiltrate (see
Figure 1). All Brown and Brenn stains for microorganisms
were negative.
Early Outcome
Mortality. One intraoperative death occurred due to in-
tractable right ventricular failure after MVR. Another pa-
tient (patient 4) who had an uncomplicated immediate post-
operative course developed staphylococcal sepsis due to
TABLE 1. Clinical cardiac findings
Case
Age/
gender Valve lesion
CHF class
(NYHA)
Pulmonary
hypertension*
1 48/F MS,TR IV Severe
2 48/F MR III Moderate
3 73/F MR III Severe
4 43/F MS  MR; TR IV Severe
5 47/F AR  AS; MR IV Moderate
6 38/F MR III Severe
7 51/F MR,AR,TR IV Severe
8 42/M AR, vegetation IV Moderate
9 55/M AR  AS II Mild
10 54/F MS  MR III Severe
AR, Aortic regurgitation; AS, aortic regurgitation; CHF, congestive heart
failure; MR, mitral regurgitation; MS, mitral stenosis; TR, tricuspid regur-
gitation.
*Systolic pressure by echocardiography or direct measurement (mild
30 – 45, moderate 45– 60, severe  60 mm Hg).
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mediastinal wound infection 2 weeks after surgery. Sepsis
was complicated by disseminated intravascular coagulation
(DIC), resulting in cardiac tamponade and acute hemody-
namic collapse. Pericardial drainage was performed; how-
ever, the patient died due to septic shock with multiorgan
failure.
Early complications. In 1 case (patient 8) surgery was
complicated by acute respiratory distress syndrome after
pulmonary hemorrhage on the second postoperative day.
This patient recovered gradually without mechanical venti-
lation. Patient 10 suffered from transient dysarthria and left
hemiparesis 3 weeks after the operation. She had an INR of
3 upon admission.
Late Outcome
Mortality. Patient 2 underwent emergency reoperation
due to stuck mitral prosthesis after 7.5 years of clinical
stability. A pseudoaneurysm then developed at the level of
mitral annulus and the patient died as a result of a technical
complication related to reoperation.
The postoperative course of patient 3 was uneventful
apart from persistent pulmonary hypertension. One year
later her hemolytic anemia worsened. Renal failure neces-
sitating hemodialysis developed, and the patient died of
pulmonary insufficiency with rapid progression to multior-
gan failure.
Complications. Patient 8 underwent reoperation 15
months after his first operation because of partial detach-
ment of the aortic homograft and fresh tear in the left leaflet
with severe valvular and paravalvular leak. There was no
evidence of infective etiology, and this time the postopera-
tive course was uneventful.
Patient 5 had an uncomplicated operation. Three months
after operation she was hospitalized with splenic infarction
TABLE 2. Clinical data
Case
Disease
duration
(y)
History of
abortion
History of
thromboembolism CNS Thrombocytopenia Anemia CRF SLE Medications
1 14 No Yes Yes Yes Yes Yes Yes P, Cy, C
2 8 Yes No Yes Yes Yes No No P, C
3 10 No Yes Yes Yes Yes Yes No P, C, A
4 10 Yes Yes Yes Yes Yes Yes Yes P, C
5 1 No Yes No Yes Yes Yes No P, C, A
6 15 Yes No Yes No Yes No Yes P, Cy, A
7 9 No Yes Yes Yes No No Yes P, Cy
8 1 Male Yes Yes Yes Yes No No No
9 7 Male Yes Yes Yes No Yes No C, A
10 22 No Yes Yes No No No Yes C
A, Aspirin; C, Coumadin; CNS, central nervous system involvement; CRF, chronic renal failure, creatinine  130 mEq/dL; Cy, cyclophosphamide.
TABLE 3. Operative data and outcome
Case Procedure Incision
Bypass/cross
clamp time
Minimal
temperature
(°C)
Cardiotonic
support
Operative
outcome
Late outcome
(mo)
Follow-up
(mo)
1 MVR (CM), TA Sternotomy 243/126 24  Death, day 1
2 MVR (CM) Sternotomy 94/52 25  Re-MVR 90
Death 96
3 MVR (HC) Sternotomy 130/80 28  Death 13
4 MVR (SJM), TA Sternotomy 127/61 27  Death, day 22
5 MVR (CM), AVR (CM) Sternotomy 123/85 28  Splenic embolus (3) 42
stroke (10)
6 MVR (CM) Thoracotomy 67/46 34  32
7 MVR (CM) Sternotomy 107/70 30  33
8 AVR (homograft) Sternotomy 140/102 30  ARDS, day 1 Re-AVR (15) 52
9 AVR (CM) Sternotomy 110/84 30  7
10 MVR (SJM) Sternotomy 71/41 31  TIA, day 21 6
ARDS, Adult respiratory distress syndrome; AVR, aortic valve replacement; CM, CarboMedics; HC, Hancock; MVR, mitral valve replacement; SJM, St Jude
Medical; TA, tricuspid annuloplasty; TIA, transient ischemic attack.
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and 10 months postoperatively she had a large stroke. Her
INR was below the recommended therapeutic range during
both thromboembolic episodes.
Moderate pulmonary hypertension persisted in 2 patients
with preoperative severe hypertension (patients 3 and 4).
The 6 long-term survivors have no symptoms of congestive
heart failure (NYHA class I). Prosthetic valve function is
normal and all have normal or only mildly elevated systolic
pulmonary artery pressure.
Altogether, there were 4 deaths among these 10 patients
with APLS undergoing valve replacement, of which 2 were
late. Early complications, including mortality, occurred in 4
cases. Two patients had late thromboembolic complications.
There were no serious late bleeding complications during
281 patient-months of follow-up in the surviving patients.
Late structural deterioration occurred in 1 (homograft) of 2
biological valves implanted. The late outcomes were un-
eventful in only 4 patients. During a follow-up period of up
to 8 years, 4 of 8 surviving patients suffered major
complications.
Discussion
Several cardiac manifestations have been reported in pa-
tients with APLS, including valvulopathy, intracardiac
thrombosis, coronary artery disease, and cardiomyopa-
thy.22-24 Various valvular lesions have been demonstrated
by echocardiography in 35% to 82% of patients.4,23 Irreg-
ular thickening of the mitral valve, followed by the aortic
valve, is the most common finding. Mitral regurgitation is
the predominant hemodynamic dysfunction, followed by
aortic regurgitation. In many cases more than 1 valve is
involved.5,22
The pathogenesis of valvulopathy is not entirely clear but
it is related to ACL antibodies. A correlation between ACL
titer and valvular lesion was found.4 Immunoglobulin (in-
cluding ACL antibodies) and complement deposits have
been demonstrated in the subendothelial layer of the af-
fected valve, implying that immune complexes may be
involved in the pathogenesis.7 Current data suggest an im-
portant role for endothelial activation. It has been suggested
that the hypercoagulable state may cause deposition of
fibrin and platelets on the valves.25 These mechanisms
could lead to inflammation with subsequent fibrosis, throm-
bosis, and calcification of the valvular tissue. The signifi-
cance of the presence of ACL antibodies in patients with
valvular heart disease not fulfilling the criteria of APLS is
not clear yet, although recent evidence suggests an in-
creased risk of thromboembolic events in such patients.26
Only rarely (about 4% to 6%) do patients with APLS
develop severe valvular disease that requires surgical treat-
ment.5
Figure 1. Section of a mitral valve from a patient with systemic lupus erythematosus and secondary antiphos-
pholipid antibody syndrome. The valve is somewhat thickened but not fibrotic in this case. Shown in the left half
of the field is a fibrinous vegetation loosely attached to the valve surface, beneath which are small, irregular
vascular spaces (neovascularization, asterisk). Inflammation is scant. (Hematoxylin & eosin, original magnification
50.)
Berkun et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 2 417
A
CD
In our retrospective study we observed high morbidity
and mortality in patients with APLS who underwent valve
replacement. The operative mortality following isolated
MVR averaged 6.04% in 16,105 operated patients from the
Society of Thoracic Surgeons (STS) National Cardiac Sur-
gery Database who underwent this procedure; operative
mortality was significantly increased by various associated
conditions.27 Little is known about heart valve replacement
in patients with APLS, as data regarding this intervention
are limited to several case reports only. A summary of
reported cases (Table 4) shows 3 deaths among 17 operated
patients with APLS, 2 of them during the perioperative
period, similar to our observation. In most of these cases,
the follow-up was not reported.6-19
The high mortality and the increased morbidity observed
in our experience may be accounted for by several factors.
These include comorbid states and the consequences of
treatment of these conditions and the advanced nature of the
valvular heart disease at the time of surgical intervention.
In half of our patients, APLS was secondary to SLE.
Results of valve replacement in patients with SLE were
described in several case reports and small series only. In a
review that summarizes case reports of 12 patients with SLE
(with unknown ACL status) who had a total of 14 valves
replaced, operative mortality was 25%.28
Most of our patients received steroids or other immuno-
suppressive drugs. Such treatment doubled the operative
mortality after either AVR or MVR among 49,073 patients
in the STS database.27
Mild renal failure, which did not require dialysis, pre-
vailed in 5 of our patients. Renal involvement occurs in as
many as 25% of patients with the primary APLS.29 Renal
failure is known to be associated with both increased early
mortality and late complications in valve replacement.27,30
Coexisting thrombophilia and significant thrombocyto-
penia may also complicate the operative management of
patients with APLS.18,19 Perioperative thrombosis may be
due to antiphospholipid antibodies, warfarin withdrawal
before the operation, and catastrophic exacerbation of
APLS.31,32 Cardiopulmonary bypass with its inherent co-
agulopathy may augment the bleeding tendency in such
patients. Pulmonary apoplexy occurred in 1 of our patients
in the early postoperative period. If bleeding diathesis is not
observed in the immediate postoperative period, it should be
realized that the patients are at increased risk of thrombo-
embolism with significant CNS complications. Therefore,
early institution of antiplatelet therapy, in addition to anti-
coagulant treatment, should be strongly considered.
All but 1 of our patients had either CNS involvement or
a history of stroke. Cerebral ischemia is the most common
arterial thrombotic manifestation of APLS and is known to
be an important cause of morbidity and mortality in this
condition.33 This is also another risk factor for cardiac
surgery, carrying an odds ratio of 1.23 in the STS data-
base.27
The treating physician should be aware of the multiple
comorbidities in these patients, which will obviously in-
crease the complexity of the medical and surgical care. This
in itself should not preclude these patients from surgery. It
would be prudent, however, to apply a multidisciplinary
approach in the management of such patients.
With regard to the preoperative cardiopulmonary status
of our patients, it is noteworthy that severe pulmonary
hypertension was observed in 6 cases. Pulmonary hyperten-
sion as a part of APLS is due to pulmonary vasculopathy
and pulmonary thromboembolism even in the absence of
mitral disease.1 Despite new medical regimens for pulmo-
nary hypertension, mortality remains high after surgical
procedures in such cases.33 This condition is also associated
with increased mortality and could adversely affect the
course after cardiac surgery.27 Of note, pulmonary pressure
in our long-term survivors has returned to normal or near-
normal values.
Progressive heart failure (NYHA class IV), present in 5
of our patients, is also known to increase the operative risk
by 1.36.27
As the patients should be treated with anticoagulation
due to their hypercoagulopathy, we elected to use a me-
chanical prosthesis in most cases. Only 2 patients received
biological valves because of their own preference. As the
valvular involvement in this disease is immunologically
mediated, the question arises whether a homograft valve
implanted in such patients may be subjected to rapid im-
munological destruction. We do not have evidence as yet for
such. Replacement with a mechanical valve may also min-
TABLE 4. Literature summary
First author Procedure
Mortality/
operated Follow-up
Turiel4 MVR 1/1 Operative death
Alvarez-Blanco6 MVR 0/1 Not available
Amital7 MVR 0/1 Not available
Araki8 MVR 1/1 Death at 1 year
Hasegawa9 MVR 0/1 Not available
Hogan10 AVR 0/1 Uneventful, 1.4
year
Galve11 MVR 1/1 Operative death
Kato12 MVR 0/1 CNS thrombosis,
re-MVR at 9
years
Matsuyama13 AVR 0/1 Not available
Myers14 AVRMVR 0/1 Not available
Noji15 MVR 0/1 Uneventful, 4 years
Sakagushi16 AVR 0/1 Uneventful, 1 year
Schumacher17 MVR 0/1 Re-MVR 0.75 year
Erkan18 MVR, MVRAVR 0/2 Not available
East19 MVR 0/2 Not available
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imize the need for repeat, high-risk operations. As discussed
earlier, the impaired immunity incurred by the disease and
the immunosuppressive treatment may complicate the post-
operative course. We observed 1 major infective complica-
tion, mediastinitis evolving to generalized sepsis with DIC
and multiorgan failure.
With recently improved survival of patients with APLS
and SLE due to better medical treatment including preven-
tion of thrombosis and other complications, more patients
can be expected to survive long enough to develop progres-
sive valvular disease. As there is neither effective medical
treatment available to prevent the development of heart
valve disease nor to slow its progression, it is likely that
more patients will require valve replacement. Intraoperative
valve inspection revealed virulent tissue destruction with
significant thickening and verrucous vegetations in many
cases, confirmed by the pathological examination. There-
fore valve repair is not feasible or inappropriate, rendering
replacement as the only option. In this regard, considering
the younger age of these patients at the time of surgical
intervention and the better prognosis with intensive medical
treatment, a mechanical valve substitute may be advanta-
geous over a bioprosthesis.
Conclusion
Although our series is small and retrospective, it shows that
valve replacement in patients with APLS is associated with
significant morbidity and mortality as also suggested by
review of previously reported cases. This group of patients
is characterized by advanced valvular disease with signifi-
cant pulmonary hypertension and progressive heart failure.
Most patients are immune compromised, with renal dys-
function and previous CNS complications. Thus, to reduce
the operative risks, such patients should be closely observed
and considered for earlier operative intervention. Mechani-
cal substitutes are probably the better choice for these
patients, who are usually treated with anticoagulants for
other indications. Such policy may minimize the need for
further operative interventions carrying higher morbidity
and mortality. Prospective studies should clarify the proper
timing of operation and the optimal perioperative manage-
ment.
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